Health care costs decline after successful epilepsy surgery.
BACKGROUND
Surgery is an effective, high-cost procedure used increasingly to treat refractory epilepsy. For surgery to be cost-effective, long-term cost savings from reduced health care use should provide some offset to the initial costs of evaluation and surgery. There is little information about how health care costs are affected by evaluation and surgery.


OBJECTIVE
To determine whether health care costs change when seizures become controlled after surgery.


METHODS
Health care costs for the 2 years prior to surgical evaluation and for 2 years afterward were calculated from medical records of 68 subjects with temporal lobe epilepsy (TLE) participating in a multicenter observational study. Costs were compared among patients who did not have surgery, patients who had persisting seizures after surgery, and patients who were seizure free after surgery.


RESULTS
Antiepileptic drugs (AEDs) accounted for more than half of the costs of care in the pre-evaluation period. Total costs for seizure-free patients had declined 32% by 2 years following surgery due to less use of AEDs and inpatient care. Costs did not change in patients with persisting seizures, whether they had surgery or not. In the 18 to 24 months following evaluation, epilepsy-related costs were $2,068 to $2,094 in patients with persisting seizures vs $582 in seizure-free patients.


CONCLUSIONS
Costs remain stable over 2 years post-evaluation in patients with temporal lobe epilepsy whose seizures persist, but patients who become seizure free after surgery use substantially less health care than before surgery. Further cost reductions in seizure-free patients can be expected as antiepileptic drugs are successfully eliminated.
Langfitt
J T
JT
Department of Neurology, University of Rochester, Rochester, NY 14642, USA. john_langfitt@urmc.rochester.edu
Holloway
R G
RG
McDermott
M P
MP
Messing
S
S
Sarosky
K
K
Berg
A T
AT
Spencer
S S
SS
Vickrey
B G
BG
Sperling
M R
MR
Bazil
C W
CW
Shinnar
S
S
D000328:Adult; D000927:Anticonvulsants / Q000191:economics* / Q000627:therapeutic use; D017281:Cost of Illness; D003362:Cost-Benefit Analysis; D004827:Epilepsy / Q000188:drug therapy / Q000517:prevention & control / Q000601:surgery; D004833:Epilepsy, Temporal Lobe / Q000188:drug therapy / Q000191:economics / Q000601:surgery*; D005260:Female; D017048:Health Care Costs / Q000706:statistics & numerical data* / Q000639:trends; D006296:Health Services / Q000706:statistics & numerical data; D006801:Humans; D008297:Male; D008875:Middle Aged; D019635:Neurosurgical Procedures / Q000191:economics*; D011446:Prospective Studies; D055502:Secondary Prevention; D013702:Temporal Lobe / Q000503:physiopathology / Q000601:surgery; D013995:Time
D000927:Anticonvulsants